Literature DB >> 33706167

A gain-of-function mutation in CITED2 is associated with congenital heart disease.

Manohar Lal Yadav1, Dharmendra Jain2, Damyanti Agrawal3, Ashok Kumar4, Bhagyalaxmi Mohapatra5.   

Abstract

CITED2 is a transcription co-activator that interacts with TFAP2 and CBP/ P300 transcription factors to regulate the proliferation and differentiation of the cardiac progenitor cells. It acts upstream to NODAL-PITX2 pathways and regulates the left-right asymmetry. Both human genetic and model organism studies have shown that altered expression of CITED2 causes various forms of congenital heart disease. Therefore, we sought to screen the coding region of CITED2 to identify rare genetic variants and assess their impact on the structure and function of the protein. Here, we have screened 271 non-syndromic, sporadic CHD cases by Sanger's sequencing method and detected a non-synonymous variant (c.301C>T, p.P101S) and two synonymous variants (c.21C>A, p.A7A; c.627C>G, p.P209P). The non-synonymous variant c.301C>T (rs201639244) is a rare variant with a minor allele frequency of 0.00011 in the gnomAD browser and 0.0018 in the present study. in vitro analysis has demonstrated that p.P101S mutation upregulates the expression of downstream target genes Gata4, Mef2c, Nfatc1&2, Nodal, Pitx2, and Tbx5 in P19 cells. Luciferase reporter assay also demonstrates enhanced activation of downstream target promoters. Further, in silico analyses implicate that increased activity of mutant CITED2 is possibly due to phosphorylation of Serine residue by proline-directed kinases. Homology modeling and alignment analysis have also depicted differences in hydrogen bonding and tertiary structures of wild-type versus mutant protein. The impact of synonymous variations on the mRNA structure of CITED2has been analyzed by Mfold and relative codon bias calculations. Mfold results have revealed that both the synonymous variants can alter the mRNA structure and stability. Relative codon usage analysis has suggested that the rate of translation is attenuated due to these variations. Altogether, our results from genetic screening as well as in vitro and in silico studies support a possible role of nonsynonymous and synonymous mutations in CITED2contributing to pathogenesis of CHD.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  CITED2; Codon usage bias; Congenital heart disease; Serine phosphorylation; mRNA folding

Mesh:

Substances:

Year:  2021        PMID: 33706167     DOI: 10.1016/j.mrfmmm.2021.111741

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  3 in total

1.  A novel KLF13 mutation underlying congenital patent ductus arteriosus and ventricular septal defect, as well as bicuspid aortic valve.

Authors:  Pradhan Abhinav; Gao-Feng Zhang; Cui-Mei Zhao; Ying-Jia Xu; Juan Wang; Yi-Qing Yang
Journal:  Exp Ther Med       Date:  2022-03-01       Impact factor: 2.447

2.  Identification of a novel heterozygous SOX9 variant in a Chinese family with congenital heart disease.

Authors:  Li Gong; Chunyan Wang; Haiyang Xie; Jun Gao; Tengyan Li; Shenggui Qi; Binbin Wang; Jing Wang
Journal:  Mol Genet Genomic Med       Date:  2022-02-26       Impact factor: 2.473

3.  Functional analysis of HECA variants identified in congenital heart disease in the Chinese population.

Authors:  Ting Li; Yao Wu; Wei-Cheng Chen; Xing Xue; Mei-Jiao Suo; Ping Li; Wei Sheng; Guo-Ying Huang
Journal:  J Clin Lab Anal       Date:  2022-08-10       Impact factor: 3.124

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.